Novel Alzheimers drug

I have written many times about the expanding disaster of Alzheimer's Disease. As our population ages, conditions such as this one are on the rise and presenting an increasing burden on individuals, families and our already strapped health care system.

Alzheimer's is a particularly upsetting example because we have yet to develop any treatments that truly do much to even slow its progression.

With numbers on the rise, this condition already costs the global economy more than $600 billion a year and it is expected to double every two decades if an effective treatment or cure is not found.

In the meantime, millions suffer and their families can do little but watch helplessly as their loved one relentlessly slips into dementia.

With all of this in mind, finding a treatment breakthrough in Alzheimer's is an important goal for modern medicine and clinical research in particular.

What is known about Alzheimer's is that there are two primary characteristics noticeable in the affected brain: plaques containing beta amyloid protein and tangles containing tau protein. These structures can be found in the brain up to a decade before symptoms appear and they seem to increase in number as the disease progresses on its deadly course.

Treatment research until recently has focused primarily on symptomatic relief by manipulating neurotransmitters in the brain. Several products have made it to market with this goal, but these have had very limited success. For some patients with mild to moderate symptoms, these have improved symptoms for a short time, but have done little to slow the actual progression of the disease.

Aside from symptom management, treatment research has also focused on the beta amyloid plaques. Some products have been in the pipeline but seem to be stalled right now. Meanwhile, some research is also underway examining the tau tangles and there seems to be some promising preliminary results.

One product which targets the tau tangles showed an 80-90 percent decline over two years in a phase II study of patients with mild to moderate Alzheimer's disease Brain imaging showed the drug seemed to have the greatest effect in the tangle-heavy areas important to memory. These are early days, but phase III studies are underway to gain more insight into the potential effectiveness of this treatment.

Okanagan Clinical Trials is participating in a phase III study right now for this condition. If you or a loved one experience mild to moderate Alzheimer's disease and are aged 65 or older, you may be eligible to participate. Contact us for more information.

In the meantime, if you or a loved one are having memory troubles and are concerned about dementia, visit your doctor. There are screening tests that can determine cognitive function and help differentiate between normal memory loss from aging and more serious brain diseases.

 

Current Studies

 Alzheimer's 

 Crohn's 

 Insomnia

 Migraine

 Narcolepsy

 Parkinson's 

  Ulcerative Colitis

 

 

more

 

 

 Interested in participating? Call us for more information!

more